Exposure to secondhand aerosol of electronic cigarettes in indoor settings in 12 European countries: data from the TackSHS survey
Por:
Amalia, B, Liu, XQ, Lugo, A, Fu, M, Odone, A, van den Brandt, PA, Semple, S, Clancy, L, Soriano, JB, Fernandez, E, Gallus, S, Lopez, MJ, Continente X., TackSHS Project Investigators
Publicada:
1 ene 2021
Resumen:
Introduction Exposure to secondhand aerosol from e-cigarette (SHA) may pose harmful effects to bystanders. This study aims to investigate the prevalence, duration and determinants of SHA exposure in various indoor settings in 12 European countries.
Methods In 2017-2018, we conducted a cross-sectional study, the TackSHS survey, on a representative sample of the population aged >= 15 years in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania and Spain). We described the prevalence and duration of exposure to SHA in several indoor settings among 11 604 e-cigarette non-users. Individual-level and country-level characteristics associated with SHA exposure were also explored using multilevel logistic regression analyses.
Results Overall, 16.0% of e-cigarette non-users were exposed to SHA in any indoor setting at least weekly, ranging from 4.3% in Spain to 29.6% in England. The median duration of SHA exposure among those who were exposed was 43 min/day. 'Other indoor settings' (eg, bar and restaurant) was reported as the place where most of e-cigarette non-users were exposed (8.3%), followed by workplace/educational venues (6.4%), home (5.8%), public transportation (3.5%) and private transportation (2.7%). SHA exposure was more likely to occur in certain groups of non-users: men, younger age groups, those with higher level of education, e-cigarette past users, current smokers, those perceiving SHA harmless and living in countries with a higher e-cigarette use prevalence.
Conclusions We found inequalities of SHA exposure across and within European countries. Governments should consider extending their tobacco smoke-free legislation to e-cigarettes to protect bystanders, particularly vulnerable populations such as young people.
Filiaciones:
Amalia, B:
Catalan Inst Oncol ICO, Tobacco Control Unit, Lhospitalet De Llobregat 08908, Catalonia, Spain
Catalan Inst Oncol ICO, WHO Collaborating Ctr Tobacco Control, Lhospitalet De Llobregat, Catalonia, Spain
Bellvitge Inst Biomed Res IDIBELL, Tobacco Control Res Grp, Lhospitalet De Llobregat, Catalonia, Spain
Univ Barcelona UB, Dept Clin Sci, Lhospitalet De Llobregat, Catalonia, Spain
CIBER Resp Dis CIBERES, Madrid, Spain
Liu, XQ:
IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy
Lugo, A:
IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy
Fu, M:
Catalan Inst Oncol ICO, Tobacco Control Unit, Lhospitalet De Llobregat 08908, Catalonia, Spain
Catalan Inst Oncol ICO, WHO Collaborating Ctr Tobacco Control, Lhospitalet De Llobregat, Catalonia, Spain
Bellvitge Inst Biomed Res IDIBELL, Tobacco Control Res Grp, Lhospitalet De Llobregat, Catalonia, Spain
Univ Barcelona UB, Dept Clin Sci, Lhospitalet De Llobregat, Catalonia, Spain
CIBER Resp Dis CIBERES, Madrid, Spain
Odone, A:
Univ Vita Salute San Raffaele, Sch Publ Hlth, Milan, Lombardia, Italy
van den Brandt, PA:
Maastricht Univ Med Ctr, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands
Semple, S:
Univ Stirling, Inst Social Mkt, Stirling, Scotland
Clancy, L:
TobaccoFree Res Inst Ireland TFRI, Dublin, Ireland
Soriano, JB:
CIBER Resp Dis CIBERES, Madrid, Spain
Hosp Univ Princesa, Resp Dept, Madrid, Spain
Fernandez, E:
Catalan Inst Oncol ICO, Tobacco Control Unit, Lhospitalet De Llobregat 08908, Catalonia, Spain
Catalan Inst Oncol ICO, WHO Collaborating Ctr Tobacco Control, Lhospitalet De Llobregat, Catalonia, Spain
Bellvitge Inst Biomed Res IDIBELL, Tobacco Control Res Grp, Lhospitalet De Llobregat, Catalonia, Spain
Univ Barcelona UB, Dept Clin Sci, Lhospitalet De Llobregat, Catalonia, Spain
CIBER Resp Dis CIBERES, Madrid, Spain
Gallus, S:
IRCCS Ist Ric Farmacol Mario Negri, Dept Environm Hlth Sci, Milan, Italy
Lopez, MJ:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Continente X.:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Green Accepted
|